| Name | PureTech Health |
|---|---|
| Epic | PRTC |
| Isin | GB00BY2Z0H74 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 132.20p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £319.51 | Debt ratio | n/a |
| Shares in issue | 241.68 | Debt-to-equity ratio | n/a |
| P/E ratio | 9.6 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 4.42 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | 21 | 52-week high / low | 103.00p / 173.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | PureTech Health |
|---|---|
| Address | 6 Tide St Ste 400, Boston, United States, MA, 02210 |
| Telephone | +1 617 482 2333 |
| Website | http://www.puretechhealth.com |
| Director | Position |
|---|---|
| Dr. Robert Langer | Non-Executive Director |
| Mr H. Robert Horvitz | Non-Executive Director |
| Ms Sharon Barber-Lui | Interim Chairman |
| Mr Michele Holcomb | Independent Non-Executive Director |
| Ms Kiran Mazumdar Shaw | Independent Non-Executive Director |
| Dr. John LaMattina | Independent Non-Executive Director |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 0.6 | 0.91 | 0.83 |
| Investments and other non-current assets | 200.17 | 325.63 | 277.54 |
| Total non-current assets | 216.38 | 346.77 | 316.45 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.52 | 2.38 | 33.97 |
| Cash and equivalents | 280.64 | 191.08 | 149.87 |
| Other current assets and asset held for resale | 6.05 | 17.68 | 2.12 |
| Total of all assets | 602.64 | 693.97 | 702.65 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 41.39 | 51.37 | 96.88 |
| Long term liabilities | 153.31 | 184.37 | 58.17 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 194.7 | 235.74 | 155.06 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 407.93 | 458.23 | 547.59 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 4.86 | 5.46 | 5.46 |
| Minority interests | -6.77 | -5.83 | 5.37 |
| Retained earnings | 32.49 | 83.82 | 149.52 |
| Share premium account | 290.26 | 290.26 | 289.62 |
| Total equity | 407.93 | 458.23 | 547.59 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -136.09 | -146.2 | -197.81 |
| Pre-tax profit | 23.77 | -36.1 | -92.78 |